A single-arm, open-label, phase II trial of the tumour response to entrectinib in patients with advanced tumours harbouring NTRK fusions or ROS1 gene rearrangements detected by comprehensive genomic profiling
Latest Information Update: 18 Apr 2022
At a glance
- Drugs Entrectinib (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms MoST Addendum 13
- 20 Oct 2021 Planned initiation date changed from 1 Apr 2021 to 31 Dec 2021.
- 20 Oct 2021 Status changed from not yet recruiting to recruiting.
- 19 Mar 2021 New trial record